Detection of the effects and potential interactions of FSH, VEGFA, and 2‐methoxyestradiol in follicular angiogenesis, growth, and atresia in mouse ovaries
article
OA: closed
CC0
AI-generated summary
This study investigated how VEGF120, FSH, and 2ME2 affect follicular development, angiogenesis, and atresia in mouse ovaries, finding they have specific roles in these processes, with FSHR being crucial for VEGFA function.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Ovarian follicular development is a complex process that requires codevelopment of the perifollicular vascular network, which is closely regulated by angiogenic factors, gonadotropins, sex steroids, and their metabolites. To detect the effects of vascular endothelial growth factor 120 (VEGF120), follicle-stimulating hormone (FSH), and 2-methoxyestradiol (2ME2) on follicular angiogenesis during development and atresia, we treated sexually immature and mature female mice with VEGF120, FSH, 2ME2, and FSH receptor (FSHR) antagonist singly or in combination via intraperitoneal injection. The number of follicles and their perifollicular angiogenesis and atresia rates at different developmental stages were examined in paraffin sections after hematoxylin and eosin staining. The results showed that the exogenous factors have specific and precise effects on developmental, angiogenesis, and atresia processes in follicles of different sizes in mature and immature mice. Perifollicular angiogenesis was regulated by VEGFA and closely related to follicular development and atresia. 2ME2 affected angiogenesis through VEGFA and might regulate atresia directly. FSH might control VEGFA function via both transcriptional and posttranscriptional mechanisms because FSHR was required for achieving VEGFA functions at all the follicular development stages. The present study presents insights into the mechanisms of FSH, 2ME2, and VEGFA in follicular development and disorders and provides a foundation for the development of new therapeutic strategies.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (48)
- W198469451 via openalex
- W1499718428 via openalex
- W1670263292 via openalex
- W1868088927 via openalex
- W1972926354 via openalex
- W1977265534 via openalex
- W1977626009 via openalex
- W1985359220 via openalex
- W2008188698 via openalex
- W2037913447 via openalex
- W2054281234 via openalex
- W2057366643 via openalex
- W2059454385 via openalex
- W2063027760 via openalex
- W2066565504 via openalex
- W2069337830 via openalex
- W2076480166 via openalex
- W2076960363 via openalex
- W2077129920 via openalex
- W2078282845 via openalex
- W2083835054 via openalex
- W2084179156 via openalex
- W2092221251 via openalex
- W2093096968 via openalex
- W2107277218 via openalex
- W2110187331 via openalex
- W2110995758 via openalex
- W2111393133 via openalex
- W2111622585 via openalex
- W2120847343 via openalex
- W2126009783 via openalex
- W2128242453 via openalex
- W2129425050 via openalex
- W2130503782 via openalex
- W2136979143 via openalex
- W2137215560 via openalex
- W2137918853 via openalex
- W2148353329 via openalex
- W2150173675 via openalex
- W2166156136 via openalex
- W2166435019 via openalex
- W2167154418 via openalex
- W2169525543 via openalex
- W2171500397 via openalex
- W2388624696 via openalex
- W2504924781 via openalex
- W2512297838 via openalex
- W2596321460 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-06-13T17:26:54.343160+00:00
License: CC0
· commercial use OK